Re-Evaluating GDMT in Heart Failure

Published: 27 March 2023

  • Views:

    Views Icon 16982
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


This video series is dedicated to re-evaluating guideline-directed medical therapy (GDMT) in patients with heart failure (HF). 

Spilt into two short videos, in the first part Dr Gianluigi Savarese (Karolinska Institute, Stockholm, SE) and Dr Biykem Bozkurt (Baylor College of Medicine, Texas, US) discuss the most recent changes to clinical practice guidelines and consider the clinical trial evidence that is yet to be incorporated by guideline writing committees and what this may mean for future practice.

Following this, Dr Gianluigi Savarese (Karolinska Institute, Stockholm, SE) and Dr Orly Vardeny (University of Minnesota, Minneapolis, US) discuss the current trends in the utilisation of GDMT in patients with HF including the implementation of new therapies and barriers to their initiation.

This programme is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Identify the updates captured in the ACC/AHA/HFSA 2022 guidelines with respect to foundational therapy choice and implementation approach in HF patients
  • Recall the clinical outcomes from pivotal trials that were published after the ACC/AHA/HFSA 2022 guidelines
  • Postulate how clinical practice may be impacted by recent clinical data
  • Describe the current trend with the use of GDMT in HF patients
  • Adopt newer drug classes as part of a guideline-directed approach to treat HF

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Primary Care Specialists
  • Nurses
  • Pharmacists
  • Other Allied HCPs

More from this programme

Part 1

Accommodating New Evidence in HF Guidelines

In this video, Dr Savarese and Dr Bozkurt summarise the 2022 American guidelines new recommendations for pharmacological agents in HF and the evidence that was unavailable in the 2021 European guidelines. They also discuss the key clinical endpoints in the SGLT-2 inhibitors trials and how these agents will be applied in clinical practice. 

Part 2

Current Trends in HF GDMT

In this video, Dr Savarese and Dr Vardeny discuss the recent guideline recommendations for four pillar GDMT and how well these are being utilised in clinical practice for patients with HF. They also discuss the barriers in utilisation of the newly recommended therapies and maintaining patients on GDMT after they have been initiated. 

Faculty Biographies

Gianluigi Savarese

Gianluigi Savarese

Associate Professor of Cardiology

Dr Gianluigi Savarese is currently an Associate Professor of Cardiology and Heart Failure Specialist at the Karolinska Institute in Stockholm, Sweden. 

Dr Savarese has served on the board for the European Society of Cardiology's Heart Failure Association since 2020, and has previously been a Nucleus member of a working group on Cardiovascular Pharmacotherapy for the ESC. He is a member of the Italian Society of Cardiology, and the Swedish Society of Cardiology. 

Dr Savarese attended the University of Naples Federico II University for his degree in Surgery and Medicine between 2004 - 2010. He then went on to stay at the same institution until 2016 as he completed his Specialism in Cardiovascular Diseases. He then continued his postgraduate studies at the University of Zurich between 2015-2017, where he continued his studies into Heart Failure. Finally, Dr Savarese completed his PhD at the Karolinska Institutet in 2018. 

Dr Savarese…

View full profile
Biykem  Bozkurt

Biykem Bozkurt

Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America. 

Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine. 

View full profile
Orly Vardeny

Orly Vardeny

Associate Professor of Medicine

Dr Orly Vardeny is Associate Professor of Medicine at the University of Minnesota in Minneapolis. Her research interests include maximising the benefit of pharmacologic therapy in patients with heart failure and optimising vaccination strategies in patients with cardiac disorders. She has led several multi-center, randomized clinical trials evaluating influenza vaccines in patients with high-risk cardiovascular disease.

In addition, Dr Vardeny serves as the US national lead investigator and a steering committee member for numerous clinical trials investigating novel therapies in patients with heart failure. Her clinical practice is in the outpatient management of patients with chronic heart failure. She is an Associate Editor for Circulation: Heart Failure and was a writing group member for the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guidelines for the Management of Heart Failure.

View full profile


You must be to comment. If you are not registered, you can register here.